Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib The Children’s Oncology Group AAML0631 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results